Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer
Status:
Recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This is a phase III randomized controlled trial comparing the efficacy and safety of
FOLFOXIRI versus CapeOX as neoadjuvant regimen in treating patients with middle and upper
locally advanced (MRI T3-4 or N+) rectal cancer. This study aims to optimize the neoadjuvant
therapy for patients with anus-preserving resectable locally advanced rectal cancer, so as to
improve the prognosis of them. It remains unclear about whether FOLFOXIRI or CapeOX
neoadjuvant chemotherapy is more effective for locally advanced rectal cancer.